Standout Papers

Therapeutic options in VEXAS syndrome: insights from a retrospective series 2021 2026 2022 2024157
  1. Therapeutic options in VEXAS syndrome: insights from a retrospective series (2021)
    Estelle Bourbon, Maël Heiblig et al. Blood

Immediate Impact

60 standout
Sub-graph 1 of 23

Citing Papers

Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives
2025 Standout
Cancer stem cells and niches: challenges in immunotherapy resistance
2025 Standout
2 intermediate papers

Works of Maël Heiblig being referenced

Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
2022
Cardio-Vascular Events Occurring On Ponatinib In Chronic Phase Chronic Myeloid Leukemia Patients, Preliminary Analysis Of a Multicenter Cohort
2013

Author Peers

Author Last Decade Papers Cites
Maël Heiblig 269 403 450 68 756
Serena Merante 540 478 334 40 807
Bhavisha A. Patel 315 317 330 68 842
S Eridani 615 465 179 69 987
Emma M. Groarke 305 281 276 54 660
Claudia Baratè 495 490 204 56 981
Chiara Maria Dellacasa 446 413 164 37 732
Eri Kawata 448 320 173 42 824
R. Fischer 361 337 120 41 729
Mario Annunziata 574 251 108 51 753
Pedro Enrique Dorlhiac‐Llacer 655 575 402 38 803

All Works

Loading papers...

Rankless by CCL
2026